Ken Griffin Biocept Inc Call Options Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2023

May 15, 2023
SELL
$0.24 - $0.62 $8,304 - $21,452
-34,600 Reduced 87.82%
4,800 $1,000
Q4 2022

Feb 14, 2023
SELL
$0.47 - $0.89 $6,956 - $13,172
-14,800 Reduced 27.31%
39,400 $20,000
Q3 2022

Nov 14, 2022
SELL
$0.75 - $1.2 $45,225 - $72,360
-60,300 Reduced 52.66%
54,200 $50,000

About BIOCEPT INC

BIOC Quotes by TradingView
  • Ticker BIOC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 16,922,900
  • Market Cap $1.18M
  • Description
  • Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for ...
More about BIOC
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email